Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors through vertical inhibition of RAS, RAF and MEK. </title>
Silvia Coma(Verastem (United States)), Jonathan A. Pachter(Verastem (United States)), Cristina Caffarra, Mariano Barbacid(Spanish National Cancer Research Centre), Chiara Ambrogio(Dana-Farber Cancer Institute), Mónica Musteanu(Universidad Complutense de Madrid), Alessia Mira(University of Turin), Enrico Patrucco(University of Turin), Andrew J. Aguirre(Broad Institute), Julien Dilly(Massachusetts Institute of Technology)
Cited by 3
Related Papers
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Activated Kras and <i>Ink4a/Arf</i> deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
|Genes & Development|2003|1k
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
|Cancer Discovery|2016|632
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
|Cell|2021|586
Both p16 <sup>Ink4a</sup> and the p19 <sup>Arf</sup> -p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse
|Proceedings of the National Academy of Sciences|2006|585